

Date: 12.02.2019

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai - 400 001

Sub: Submission of Un-Audited Standalone Financials Results of the Company and Limited Review Report as per Provisions of Regulation 30, 33 of SEBI (LODR) Regulations, 2015.

Please find enclosed here with the following Documents in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015:

1. Financial Results: Un-Audited Standalone Financial Results of the company for the Third Quarter ended 31st December, 2018.
2. Limited Review Report: A Certified Copy of the Limited Review Report on Standalone Financials for the Third Quarter ended 31st December, 2018 by the Auditors.

This is for your Information and Necessary Records.

Thanking you
For **TRIMURTHI LIMITED**


Arun Kumar Bhangadia
Managing Director
DIN: 00021024

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

Date: 12.02.2019

To,
The Secretary,
The B.S.E Limited
Floor 25, P.J. Towers,
Dalal Street,
Mumbai- 400 001

Sub: Outcome of the Board Meeting held on 12/02/2019 as per Regulation 30, 33 of SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

The Board of Directors of the Company at its meeting held today, Tuesday, the 12th day of February, 2019 at Registered Office, have approved and taken on record the following:


1. The Board has considered and approved the minutes of the previous board meeting.
2. The Board has considered and approved the Unaudited Standalone Financial Results for the Third Quarter ended 31st December, 2018 along with Limited Review Report issued by the Statutory Auditors of the Company in compliance with Indian Accounting Standards (Ind-AS), SEBI (LODR) Regulations, 2015 and Schedule III of Companies Act, 2013.

There being no other matter meeting of the Board of Directors concluded with the vote of thanks.

The Meeting of the Board of Directors of the company commenced at 03.30 P.M. and Concluded at 04:30 PM

Request you to take same on records.

Thanking you
for TRIMURTHI LIMITED


Arun Kumar Bhangadia
Managing Director
TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)
4-4-231/1/2/ABC, Inder Bagh, Sultan Bazar, Hyderabad - 500095.
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS
FOR THE QUARTER III AND NINE MONTHS ENDED 31ST DECEMBER 2018

TRIMURTHI
GROUP

Rs. in Lakhs

PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED	
	31.12.2018 (UNAUDITED)	30.09.2018 (UNAUDITED)	31.12.2017 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2017 (UNAUDITED)
1. INCOME					
INCOME FROM OPERATIONS	98.89	107.03	104.54	310.36	182.67
OTHER INCOME	(0.31)	1.54	0.06	2.10	2.22
TOTAL INCOME	98.57	108.58	104.60	312.45	184.89
2. EXPENSES					
PURCHASES	89.56	85.11	111.17	250.31	114.25
COST OF MATERIALS CONSUMED	-	-	-	-	-
MANUFACTURING EXPENSES	-	-	-	-	-
WORK IN PROGRESS AND STOCK IN TRADE	(7.30)	-	(29.36)	(0.14)	(7.97)
RENT	1.00	0.60	0.95	2.25	2.25
EMPLOYEE BENEFITS EXPENSE	9.95	8.48	7.52	24.65	18.80
FINANCE COSTS	-	-	-	-	-
DEPRECIATION AND AMORTISATION EXPENSES	2.80	2.99	4.26	8.81	11.96
OTHER EXPENSES	2.17	7.78	3.41	21.69	11.51
TOTAL EXPENSES	98.19	104.96	97.95	307.58	150.80
3. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE EXCEPTIONAL ITEMS (1-2)	0.39	3.62	6.65	4.88	34.09
4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS					
5. PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (3-4)	0.39	3.62	6.65	4.88	34.09
6. TAX EXPENSES	(4.74)	(2.20)	1.52	(9.44)	8.49
-CURRENT TAX	0.70	(0.29)	2.85	0.70	10.14
-TAX ADJUSTMENTS RELATING TO EARLIER YEARS	-	-	-	-	-
-DEFERRED TAX (NET)	(5.44)	(1.91)	(1.33)	(10.14)	(1.65)
7. NET PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER TAX (5-6)	5.13	5.82	5.13	14.31	25.60
8. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS					
9. TAX EXPENSES FOR DISCONTINUED OPERATIONS					
10. PROFIT/(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8-9)					
11. PROFIT/(LOSS) FOR THE PERIOD (7+10)	5.13	5.82	5.13	14.31	25.60
12. OTHER COMPREHENSIVE INCOME					
A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS					
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS	-	-	-	-	-
B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS	(2.30)	(3.25)	-	(10.12)	-
(ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS					
13. TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME)	2.82	2.57	5.13	4.19	25.60
14. EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION) :					
(i) BASIC	0.06	0.07	0.06	0.18	0.32
(ii) DILUTED	0.06	0.07	0.06	0.18	0.32
15. EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION) :					
(i) BASIC					
(ii) DILUTED					
16. EARNINGS PER EQUITY SHARE (FOR CONTINUING AND DISCONTINUING OPERATION) :					
(i) BASIC	0.06	0.07	0.06	0.18	0.32
(ii) DILUTED	0.06	0.07	0.06	0.18	0.32

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956



TRIMURTHI LIMITED
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)



TRIMURTHI
GROUP

SCHEDULE III OF THE COMPANIES ACT 2013

PART-II

	PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED	
		31.12.2018 (UNAUDITED)	30.09.2018 (UNAUDITED)	31.12.2017 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2017 (UNAUDITED)
A.	PARTICULARS OF SHARE HOLDING					
1.	Public Share Holding					
	- Number of Shares	2900600	2900600	2900600	2900600	2900600
	- Percentage of shareholding	35.81%	35.81%	35.18%	35.18%	35.81%
2.	Promoters and promoter group shareholding					
	a. Pledged / encumbered					
	- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
	- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
	- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
	b. Non encumbered					
	- No of Equity Shares	5199400	5199400	5199400	5199400	5199400
	- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.19%	64.19%	64.19%

Particulars	3 Months Ended (31/12/2018)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

Segment Reporting

	PARTICULARS	QUARTER ENDED			NINE MONTHS ENDED	
		31.12.2018 (UNAUDITED)	30.09.2018 (UNAUDITED)	31.12.2017 (UNAUDITED)	31.12.2018 (UNAUDITED)	31.12.2017 (UNAUDITED)
1.	Segment Revenue					
	a. Pharma Business	0.00	0.00	0	0.00	0.00
	b. Financial Services	14.13	13.83	19.91	44.94	63.06
	c. Investments	(0.23)	2.08	0.00	1.85	0.00
	d. Trading in Shares	3.56	6.00	84.70	20.83	121.83
	e. Foods	81.10	86.67	0	244.82	0.00
	Total	98.57	108.58	104.61	312.45	184.89
	Less: Inter Segment Revenue	-Nil-	-Nil-	Nil	Nil	Nil
	Net Sales/ Income From Operations	98.57	108.58	104.61	312.45	184.89
2.	Segment Profits (Before tax & Interest From Each Segment)					
	a. Pharma Business	0.00	0.00	0.00	0.00	0.00
	b. Financial Services	11.85	11.19	14.02	36.68	44.40
	c. Investments	(0.23)	2.08	0.00	1.85	0.00
	d. Trading in Shares	2.44	4.94	(7.37)	9.16	(10.31)
	e. Foods	(13.67)	(14.60)	0.00	(42.82)	0.00
	Total	0.40	3.62	6.65	4.88	34.09
	Less:					
	i. Interest	-Nil-	-Nil-	Nil	Nil	Nil
	ii. Other Un-allocable expenses net off	-Nil-	-Nil-	Nil	Nil	Nil
	iii. Un-allocable Income	-Nil-	-Nil-	Nil	Nil	Nil
	Total Profit Before Tax	0.40	3.62	6.65	4.88	34.09
3.	Capital Employed					
	a. Pharma Business	0.00	0.00	0.00	0.00	0.00
	b. Financial Services	15.78	(9.66)	(43.43)	537.96	601.72
	c. Investments	(3.77)	(40.81)	0.00	268.24	184.34
	d. Trading in Shares	10.80	41.76	46.74	368.10	399.39
	e. Foods	(19.96)	12.33	0.00	12.15	0.00
	Total	2.84	3.63	3.31	1186.43	1185.45

Notes:

- The format for the Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply
- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 12th February 2019. The limited review of the financial results for the Quarter ended 31st December 2018 has been carried out by the statutory auditors of the Company.
- The above standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.

Place : Hyderabad


Date : 12th February 2019

TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

For and on behalf of the Board

By Managing Director and Chief Financial Officer





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA


Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

Limited Review Report- Standalone Financial Results

To
The Board of Directors,
Trimurthi Limited (Formerly known as Trimurthi Drugs & Pharmaceuticals Limited),
Hyderabad,
India.

Limited Review Report for the Quarter and Nine months ended 31stDecember, 2018.

1. We have reviewed the accompanying statement of unaudited standalone financial results of Trimurthi Limited (the 'Company') for the quarter ended 31stDecember, 2018 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015, read with SEBI Circular No. CIR/CFD/ FAC/62/ 2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company in their meeting held on 12th February, 2019. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and policies





P. MURALI & CO.,
CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
• Website : www.pmurali.com

has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/ 62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants
FRN: 007257S



A. Krishna Rao
Partner
M.No. 020085

Place: Hyderabad
Date: 12.02.2019.
